



HIV and Viral Hepatitis: Prevention, Treatment and Coinfection

Guest Editors:

Dr. Daniel Sepúlveda-Crespo

Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III (Campus Majadahonda), Madrid, Spain

Dr. Salvador Resino

Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III (Campus Majadahonda), Madrid, Spain

Deadline for manuscript submissions:

closed (24 June 2024)

Message from the Guest Editors

Since viral hepatitis and HIV share transmission routes, many HIV-infected individuals are also co-infected with HBV, HCV, and HDV. Hepatitis viruses are a leading cause of morbi-mortality worldwide, leading to cirrhosis, end-stage liver disease, hepatocellular carcinoma, and death.

Although extraordinary progress has been made in treating hepatitis C, there are still important issues without solving, particularly in treating hepatitis B and D. On the other hand, HIV attacks and weakens the immune system progressively, destroying CD4 cells and leading to AIDS progression. The prevention of HIV infection through antiretroviral therapy is a critical point in combating this infection. The number of drugs to treat HIV-infected patients is large, but none of them has solved the problem of achieving a permanent functional cure, much less the total HIV elimination of the body.

In this Special Issue, we invite contributors to publish their research on discovering drugs with novel mechanisms of action, biomolecules, or novel biological targets to provide very effective tools in treating, preventing, and eradicating these hepatitis viruses and HIV.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com